Mirae Asset Global Investments Co., Ltd. Revolution Medicines, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

$24 Billion
Q4 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 5,606 shares of RVMD stock, worth $237,245. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,606

Previous 6,041 7.2%

Holding current value

$237,245

Previous $273,000 10.26%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 27, 2025	SELL	$42.97 - $60.6 $18,691 - $26,361	-435 Reduced 7.2%	5,606 $245,000
Q3 2024 Oct 23, 2024	BUY	$36.92 - $47.94 $41,165 - $53,453	1,115 Added 22.63%	6,041 $273,000
Q2 2024 Jul 30, 2024	SELL	$30.14 - $40.68 $1.39 Million - $1.88 Million	-46,133 Reduced 90.35%	4,926 $191,000
Q1 2024 May 01, 2024	SELL	$26.56 - $33.55 $779,429 - $984,558	-29,346 Reduced 36.5%	51,059 $1.65 Million
Q4 2023 Jan 24, 2024	BUY	$18.35 - $34.12 $461,686 - $858,459	25,160 Added 45.54%	80,405 $2.31 Million
Q3 2023 Oct 26, 2023	SELL	$25.17 - $35.05 $91,971 - $128,072	-3,654 Reduced 6.2%	55,245 $1.53 Million
Q2 2023 Aug 10, 2023	BUY	$20.28 - $27.0 $135,348 - $180,198	6,674 Added 12.78%	58,899 $1.58 Million
Q1 2023 May 04, 2023	BUY	$20.76 - $30.09 $369,133 - $535,030	17,781 Added 51.62%	52,225 $1.13 Million
Q4 2022 Feb 09, 2023	BUY	$17.68 - $25.53 $95,171 - $137,427	5,383 Added 18.52%	34,444 $820,000
Q3 2022 Nov 10, 2022	BUY	$17.46 - $26.0 $161,417 - $240,370	9,245 Added 46.65%	29,061 $573,000
Q2 2022 Jul 26, 2022	BUY	$14.54 - $27.17 $288,124 - $538,400	19,816 New	19,816 $386,000

Others Institutions Holding RVMD

# of Institutions

278

Shares Held

161M

Call Options Held

260K

Put Options Held

620K

View Full List

About Revolution Medicines, Inc.

Ticker RVMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,697,600
Market Cap $3.71B
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...

More about RVMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Revolution Medicines, Inc. Transaction History